535 related articles for article (PubMed ID: 26066931)
1. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Jones CM; Campopiano M; Baldwin G; McCance-Katz E
Am J Public Health; 2015 Aug; 105(8):e55-63. PubMed ID: 26066931
[TBL] [Abstract][Full Text] [Related]
2. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
5. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
[No Abstract] [Full Text] [Related]
6. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
7. Pronounced Regional Disparities in United States Methadone Distribution.
Furst JA; Mynarski NJ; McCall KL; Piper BJ
Ann Pharmacother; 2022 Mar; 56(3):271-279. PubMed ID: 34184584
[TBL] [Abstract][Full Text] [Related]
8. Maintenance medication for opiate addiction: the foundation of recovery.
Bart G
J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
[TBL] [Abstract][Full Text] [Related]
9. Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.
Dick AW; Pacula RL; Gordon AJ; Sorbero M; Burns RM; Leslie D; Stein BD
Health Aff (Millwood); 2015 Jun; 34(6):1028-34. PubMed ID: 26056209
[TBL] [Abstract][Full Text] [Related]
10. Use and misuse of opioid agonists in opioid addiction.
Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
[TBL] [Abstract][Full Text] [Related]
11. County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
Corry B; Underwood N; Cremer LJ; Rooks-Peck CR; Jones C
Drug Alcohol Depend; 2022 Jul; 236():109495. PubMed ID: 35605533
[TBL] [Abstract][Full Text] [Related]
12. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
[TBL] [Abstract][Full Text] [Related]
13. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
[TBL] [Abstract][Full Text] [Related]
14. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
15. Methadone and buprenorphine treatments in patients with schizophrenia.
Dervaux A; Plancke L; Amariei A; Trouiller P; Tahon M; Martinetti MP; Naassila M; Cottencin O; Danel T
Schizophr Res; 2019 Jul; 209():286-288. PubMed ID: 31101511
[No Abstract] [Full Text] [Related]
16. Opioid agonist treatment for pharmaceutical opioid dependent people.
Nielsen S; Larance B; Degenhardt L; Gowing L; Kehler C; Lintzeris N
Cochrane Database Syst Rev; 2016 May; (5):CD011117. PubMed ID: 27157143
[TBL] [Abstract][Full Text] [Related]
17. Access to treatment for opioid dependence in rural America: challenges and future directions.
Sigmon SC
JAMA Psychiatry; 2014 Apr; 71(4):359-60. PubMed ID: 24500040
[No Abstract] [Full Text] [Related]
18. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
19. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Johnson B; Richert T
Harm Reduct J; 2019 May; 16(1):31. PubMed ID: 31046774
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
